USE OF THE IMPELLA ECP™ IN PATIENTS UNDERGOING AN ELECTIVE OR URGENT HIGH-RISK PERCUTANEOUS CORONARY INTERVENTION,
Role: PI,
ABIOMED, Inc.,
(07/2024 - 07/2025)
Status: Approved
SELUTION SLR™ 014 ISR: A Prospective Randomized Single Blind Multicenter Study to Assess the Safety and Effectiveness of the SELUTION SLR™ 014 Drug Eluting Balloon in the Treatment of Subjects with In-stent Restenosis,
Role: Investigator,
MedAlliance,
(06/2024 - 06/2025)
Status: Approved
SSO2 THERAPY: AMIHOT III STUDY: A MULTI-CENTER RANDOMIZED POST-APPROVAL EVALUATION OF THE DELIVERY OF INTRACORONARY HYPEROXEMIC SUPERSATURATED OXYGEN THERAPY FOR 60 MINUTES IN ANTERIOR ACUTE MYOCARDIAL INFARCTION PATIENTS WITH SUCCESSFUL REPERFUSION (VIA PCI) = SIX HOURS AFTER SYMPTOM ONSET COMPARED TO STANDARD THERAPY,
Role: Investigator,
TherOx, Inc.,
(05/2024 - 05/2025)
Status: Approved
Ultrasound-based renal sympathetic denervation as adjunctive upstream therapy during atrial fibrillation ablation: a pilot study (ULTRA-HFIB),
Role: Investigator,
ReCor Medical, Inc.,
(01/2025 - 01/2026)
Status: Approved
Impella®-Supported PCI in High-Risk Patients with Complex Coronary Artery Disease and Reduced Left Ventricular Function: The PROTECT IV Trial,
Role: PI,
ABIOMED, Inc.,
(01/2025 - 01/2026)
Status: Approved
Equity in Modifying Plaque Of WomEn with UndeRtreated Calcified Coronary Artery Disease (EMPOWER CAD),
Role: Investigator,
Shockwave Medical, Inc.,
(11/2023)
Status: Approved
ARTEMIS- Effects of ziltivekimab versus placebo on cardiovascular outcomes in patients with acute myocardial infarction,
Role: PI,
Novo Nordisk Pharmaceuticals Inc.,
(10/2024 - 10/2025)
Status: Approved
Evaluation of clinical impact of non-invasive hemodynamic monitoring to optimize preventive care of heart failure patients,
Role: Investigator,
LLU Dept. of Anesthesiology,
(09/2020 - 09/2021)
Status: Completed
National cardiogenic shock initiative,
Role: PI,
LLU Dept. of Cardiology,
(07/2020 - 07/2021)
Status: Completed
A Retrospective Analysis and Review of Patients Undergoing Impella, a Temporary Left Ventricular Support Device, Implantation for Complex Coronary Intervention or Cardiogenic Shock,
Role: PI,
LLU Dept. of Medicine,
(04/2020)
Status: Approved
Non-Profit Organization
Can Escalation Reduce Acute Myocardial Infarction Mortality in Cardiogenic Shock (CERAMICS Study),
Role: PI,
Henry Ford Health System,
(03/2023)
Status: Approved